| 产品详情 |
| Edit |   |
|---|
| Product Name | SP2509 |
|---|
| Description | Purity >98%. Lysine-specific demethylase 1 (LSD1) is a protein lysine demethylase that specifically demethylates histone H3 lysine 4 (H3K4), resulting in transcriptional repression. SP2509 is a reversible inhibitor of LSD1 (IC50 = 13 nM). It has no effect on monoamine oxidases A and B. SP2509 attenuates the binding of LSD1 to CoREST, allowing increased methylation of H3K4 and driving increased expression of p21, p27, and CCAAT/enhancer binding protein Alpha in cultured acute myeloid leukemia (AML) cells. It improves survival of mice with AML xenografts when given (25 mg/kg biweekly via intraperitoneal injection) for three weeks. Co-treatment of SP2509 with the pan-HDAC inhibitor panobinostat synergistically kills AML cells in vitro and improves survival of mice engrafted with AML cells. |
|---|
| Size | n/a |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | 3-(4-morpholinylsulfonyl)-benzoic acid (2E)-2-[1-(5-chloro-2-hydroxyphenyl)ethylidene]hydrazide, HCI-2509, LSD1 Inhibitor VII |
|---|
| Gene, Accession, CAS # | CAS: 1423715-09-6 |
|---|
| Catalog # | LS-H9980 |
|---|
| Price | |
|---|
| Order / More Info | SP2509 from LIFESPAN BIOSCIENCES INC. |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|